J
Jason E. Cain
Researcher at Hudson Institute of Medical Research
Publications - 81
Citations - 2754
Jason E. Cain is an academic researcher from Hudson Institute of Medical Research. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 24, co-authored 62 publications receiving 1998 citations. Previous affiliations of Jason E. Cain include Monash Institute of Medical Research & Hudson Institute.
Papers
More filters
Journal ArticleDOI
Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
Pawel Buczkowicz,Christine M. Hoeman,Patricia Rakopoulos,Sanja Pajovic,Louis Letourneau,Misko Dzamba,Andrew Morrison,Peter W. Lewis,Eric Bouffet,Ute Bartels,Jennifer Zuccaro,Sameer Agnihotri,Scott Ryall,Mark Barszczyk,Yevgen Chornenkyy,Mathieu Bourgey,Guillaume Bourque,Alexandre Montpetit,Francisco Cordero,Pedro Castelo-Branco,Joshua Mangerel,Uri Tabori,King Ching Ho,Annie Huang,Kathryn R. Taylor,Alan Mackay,Anne Bendel,Javad Nazarian,Jason Fangusaro,Matthias A. Karajannis,David Zagzag,Nicholas K. Foreman,Andrew M. Donson,Julia V Hegert,Amy Smith,Jennifer A. Chan,Lucy Lafay-Cousin,Sandra E. Dunn,Juliette Hukin,Chris Dunham,Katrin Scheinemann,Jean Michaud,Shayna Zelcer,David A. Ramsay,Jason E. Cain,Cameron Brennan,Mark M. Souweidane,Chris Jones,C. David Allis,Michael Brudno,Michael Brudno,Oren J. Becher,Cynthia Hawkins +52 more
TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.
Journal ArticleDOI
Hedgehog Signaling in the Maintenance of Cancer Stem Cells
Catherine R Cochrane,Catherine R Cochrane,Anette Szczepny,Anette Szczepny,D. Neil Watkins,D. Neil Watkins,D. Neil Watkins,Jason E. Cain,Jason E. Cain +8 more
TL;DR: The mounting evidence suggestive of Hh-driven CSCs in the context of haematological malignancies and solid tumours is discussed and the novel strategies that hold the potential to block many aspects of the transformation attributed to the CSC phenotype, including chemotherapeutic resistance, relapse and metastasis are discussed.
Journal ArticleDOI
Hedgehog stimulates hair follicle neogenesis by creating inductive dermis during murine skin wound healing
Chae Ho Lim,Qi Sun,Karan Ratti,Soung Hoon Lee,Ying Zheng,Makoto Takeo,Wendy Lee,Piul S. Rabbani,Maksim V. Plikus,Jason E. Cain,David H. Wang,D. Neil Watkins,Sarah E. Millar,Makoto Mark Taketo,Peggy Myung,George Cotsarelis,Mayumi Ito +16 more
TL;DR: The authors show that if Sonic hedgehog signaling is activated in the wound, an inductive dermal niche forms, enabling regeneration and hair follicle formation, demonstrating that mechanisms of scarring and regeneration are not distant from one another and that wound repair can be redirected to promote regeneration following injury by modifying a key dermal signal.
Journal ArticleDOI
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Ashish Kalra,Jaeyeon Kim,Stephan G. Klinz,Nancy Paz,Jason E. Cain,Daryl C. Drummond,Ulrik B. Nielsen,Jonathan Fitzgerald +7 more
TL;DR: Overall, this work shows how liposomal encapsulation of irinotecan can safely improve its antitumor activity in preclinical models by enhancing accumulation of its active metabolite within the tumor microenvironment.
Journal ArticleDOI
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
Ramesh K. Ramanathan,Ronald L. Korn,Natarajan Raghunand,Jasgit C. Sachdev,Ronald G. Newbold,Gayle S. Jameson,Gerald J. Fetterly,Joshua Prey,Stephan G. Klinz,Jaeyeon Kim,Jason E. Cain,Bart S. Hendriks,Daryl C. Drummond,Eliel Bayever,Jonathan Fitzgerald +14 more
TL;DR: Correlation between FMX levels in tumor lesions and nal-IRI activity suggests that lesion permeability to FMX and subsequent tumor uptake may be a useful noninvasive and predictive biomarker for nal -IRI response in patients with solid tumors.